| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associations
|
Milano, Gerard
|
|
2016
|
78 |
2 |
p. 245
|
artikel
|
| 2 |
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer
|
Yoshitomi, Seiji
|
|
2016
|
78 |
2 |
p. 289-294
|
artikel
|
| 3 |
A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer
|
Okuma, Yusuke
|
|
2016
|
78 |
2 |
p. 383-388
|
artikel
|
| 4 |
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
|
Mross, Klaus
|
|
2016
|
78 |
2 |
p. 405-417
|
artikel
|
| 5 |
A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors
|
Cao, Junning
|
|
2016
|
78 |
2 |
p. 259-269
|
artikel
|
| 6 |
Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib
|
Lam, Lisa H.
|
|
2016
|
78 |
2 |
p. 427-432
|
artikel
|
| 7 |
Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus
|
Bodnar, Lubomir
|
|
2016
|
78 |
2 |
p. 295-304
|
artikel
|
| 8 |
Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)
|
Matikas, A.
|
|
2016
|
78 |
2 |
p. 369-376
|
artikel
|
| 9 |
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma
|
Tomono, Ayana
|
|
2016
|
78 |
2 |
p. 305-312
|
artikel
|
| 10 |
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors
|
Smith, David C.
|
|
2016
|
78 |
2 |
p. 271-280
|
artikel
|
| 11 |
High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma
|
Jiang, Lin
|
|
2016
|
78 |
2 |
p. 333-339
|
artikel
|
| 12 |
Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma
|
Kahen, Elliot
|
|
2016
|
78 |
2 |
p. 313-323
|
artikel
|
| 13 |
Identifying novel therapeutic agents using xenograft models of pediatric cancer
|
Kurmasheva, Raushan T.
|
|
2016
|
78 |
2 |
p. 221-232
|
artikel
|
| 14 |
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer
|
Hata, Tsuyoshi
|
|
2016
|
78 |
2 |
p. 389-396
|
artikel
|
| 15 |
Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors
|
Chow, Laura Q. M.
|
|
2016
|
78 |
2 |
p. 433-441
|
artikel
|
| 16 |
New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma
|
Teuma, Cécile
|
|
2016
|
78 |
2 |
p. 419-426
|
artikel
|
| 17 |
Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
|
Takaoka, Toshi
|
|
2016
|
78 |
2 |
p. 397-403
|
artikel
|
| 18 |
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
|
Kim, Jwa Hoon
|
|
2016
|
78 |
2 |
p. 325-332
|
artikel
|
| 19 |
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations
|
Mizoguchi, Kosuke
|
|
2016
|
78 |
2 |
p. 377-382
|
artikel
|
| 20 |
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer
|
Fujiwara, Yutaka
|
|
2016
|
78 |
2 |
p. 281-288
|
artikel
|
| 21 |
Population pharmacokinetics of bevacizumab in cancer patients with external validation
|
Han, Kelong
|
|
2016
|
78 |
2 |
p. 341-351
|
artikel
|
| 22 |
Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma
|
Gota, Vikram
|
|
2016
|
78 |
2 |
p. 353-359
|
artikel
|
| 23 |
Response from Drs. Formica/Zaniboni to Dr. Milano
|
Formica, V.
|
|
2016
|
78 |
2 |
p. 247
|
artikel
|
| 24 |
Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients
|
Zou, Ting
|
|
2016
|
78 |
2 |
p. 249-258
|
artikel
|
| 25 |
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
|
Ferraro, D.
|
|
2016
|
78 |
2 |
p. 361-367
|
artikel
|
| 26 |
The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside
|
Zaniboni, A.
|
|
2016
|
78 |
2 |
p. 233-244
|
artikel
|
Tijdschrift beschrijving